[amazon_link asins=’B005VSXUIA,B0048Z77CC,B0792F1WNY,B01NANTT06,B00P1RQBZ0,B00D2HQG8S,B00QMZF61A,B005J1S1RY,B00KN8CSJA’ template=’ProductCarousel’ store=’finmeacur-20′ marketplace=’US’ link_id=’03a358c1-08f0-11e8-a707-f15a95cd2ac4′]
The research group, which was led by Professor Johan Frostegård, has previously demonstrated that high levels of a certain type of antibody (anti-PC) in the immune defense are linked to a reduced risk of arteriosclerosis, a common cause of thrombosis and myocardial infarction.
In the present study, the researchers focused exclusively on stroke – a blood clot in the brain – and compared 227 individuals who had suffered stroke over a 13-year period with 445 sex and age-matched controls. After controlling for other risk factors (age, sex, smoking habits, cholesterol levels, diabetes, BMI and blood pressure), they were able to show that low levels (below 30 per cent of average) of PC antibodies correlated with a higher risk of stroke, which in women meant an almost three-fold increase.
The researchers have now advanced the hypothesis that low levels of natural PC antibodies, which can be a condition of a poor immune system – contribute to the development of arteriosclerosis and its consequences, which include stroke.
Arteriosclerosis is formed by the accumulation of plaque on the walls of blood vessels, which can rupture and form a blood clot. The researchers believe that the PC antibodies react to a substance called phosphorylcholine (PC), which is a component of a class of fat molecules (phospholipids) that go to make up the plaque.